bisoprolol has been researched along with Acute Coronary Syndrome in 7 studies
Bisoprolol: A cardioselective beta-1 adrenergic blocker. It is effective in the management of HYPERTENSION and ANGINA PECTORIS.
Acute Coronary Syndrome: An episode of MYOCARDIAL ISCHEMIA that generally lasts longer than a transient anginal episode that ultimately may lead to MYOCARDIAL INFARCTION.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We have analyzed influence of genetic variants CYP2D6*3 (2549delA) and CYP2D6*4 (1846G>A), as well as other factors on effects of bisoprolol in patients with acute coronary syndrome." | 8.02 | [Patient age and CYP2D6*4/CYP2D6*3 genotype on maximal heart rate in patients after acute coronary syndrome treated with bisoprolol.] ( Boldueva, SA; Murzina, AA; Petrova, VB; Shumkov, VA; Zagorodnikova, KA, 2021) |
| "To date, many questions about the extent and cause of pharmacokinetic (PK) variability of even the most widely studied and prescribed β1-adrenergic receptor blockers, such as metoprolol and bisoprolol, remain unanswered." | 5.51 | Population Pharmacokinetic Analysis of Bisoprolol in Patients With Acute Coronary Syndrome. ( Damjanović, M; Janković, SM; Jovanović, A; Krstić, M; Maričić, B; Mihajlović, A; Milovanović, JR; Momčilović, S; Nikolić, VN; Radojković, DD; Ranković, G; Šalinger-Martinović, S; Stanojević, D; Tasić-Otašević, S; Živković, M, 2019) |
| "We evaluated change in resting heart rate (RHR) and its impact on prognosis in Chinese coronary artery disease (CAD) patients treated with bisoprolol, and also assessed drug safety and tolerability." | 5.27 | Occurrence of composite cardiac endpoints with change in resting heart rate among Chinese patients with coronary artery disease: Chinese cohort from the real-world BISO-CAD study. ( Cao, F; Chen, X; Chen, Y; Fu, G; Gan, X; Huang, S; Li, J; Liu, H; Liu, S; Liu, W; Lv, Z; Ma, T; Wang, N; Xu, D; Xu, H; Yang, M; Yang, T; Yang, X; Yang, Y; Yuan, Y; Zheng, Q; Zhou, X, 2018) |
| "The transdermal formulation of bisoprolol may be useful for the early introduction of β-blockers in patients admitted with cardiac symptoms associated with myocardial ischemia or heart failure." | 4.02 | An attempt at administering a transdermal formulation of bisoprolol in patients with acute cardiac symptoms. ( Horiuchi, N; Kobayashi, T; Kobayashi, Y; Nakamura, S; Nakanishi, H; Naruhashi, K; Nozaki, A; Okugawa, H, 2021) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (14.29) | 29.6817 |
| 2010's | 3 (42.86) | 24.3611 |
| 2020's | 3 (42.86) | 2.80 |
| Authors | Studies |
|---|---|
| Castaño-Amores, C | 1 |
| Antúnez-Rodríguez, A | 1 |
| Pozo-Agundo, A | 1 |
| García-Rodríguez, S | 1 |
| Martínez-González, LJ | 1 |
| Dávila-Fajardo, CL | 1 |
| Nozaki, A | 1 |
| Kobayashi, T | 1 |
| Naruhashi, K | 1 |
| Okugawa, H | 1 |
| Horiuchi, N | 1 |
| Nakanishi, H | 1 |
| Kobayashi, Y | 1 |
| Nakamura, S | 1 |
| Shumkov, VA | 1 |
| Zagorodnikova, KA | 1 |
| Boldueva, SA | 1 |
| Murzina, AA | 1 |
| Petrova, VB | 1 |
| Chen, Y | 1 |
| Yang, X | 1 |
| Huang, S | 1 |
| Fu, G | 1 |
| Chen, X | 1 |
| Yang, Y | 1 |
| Liu, S | 1 |
| Xu, H | 1 |
| Ma, T | 1 |
| Zhou, X | 1 |
| Lv, Z | 1 |
| Yang, M | 1 |
| Gan, X | 1 |
| Xu, D | 1 |
| Cao, F | 1 |
| Liu, H | 1 |
| Li, J | 1 |
| Zheng, Q | 1 |
| Wang, N | 1 |
| Yuan, Y | 1 |
| Liu, W | 1 |
| Yang, T | 1 |
| Pham, D | 1 |
| Addison, D | 1 |
| Kayani, W | 1 |
| Misra, A | 1 |
| Jneid, H | 1 |
| Resar, J | 1 |
| Lakkis, N | 1 |
| Alam, M | 1 |
| Momčilović, S | 1 |
| Milovanović, JR | 1 |
| Janković, SM | 1 |
| Jovanović, A | 1 |
| Tasić-Otašević, S | 1 |
| Stanojević, D | 1 |
| Krstić, M | 1 |
| Šalinger-Martinović, S | 1 |
| Radojković, DD | 1 |
| Damjanović, M | 1 |
| Živković, M | 1 |
| Maričić, B | 1 |
| Ranković, G | 1 |
| Mihajlović, A | 1 |
| Nikolić, VN | 1 |
| Erne, P | 1 |
| Schoenenberger, AW | 1 |
| Zuber, M | 1 |
| Burckhardt, D | 1 |
| Kiowski, W | 1 |
| Dubach, P | 1 |
| Resink, T | 1 |
| Pfisterer, M | 1 |
1 review available for bisoprolol and Acute Coronary Syndrome
| Article | Year |
|---|---|
Outcomes of beta blocker use in cocaine-associated chest pain: a meta-analysis.
Topics: Acute Coronary Syndrome; Adrenergic beta-Antagonists; Atenolol; Bisoprolol; Carvedilol; Cocaine; Hum | 2018 |
2 trials available for bisoprolol and Acute Coronary Syndrome
| Article | Year |
|---|---|
Occurrence of composite cardiac endpoints with change in resting heart rate among Chinese patients with coronary artery disease: Chinese cohort from the real-world BISO-CAD study.
Topics: Acute Coronary Syndrome; Adrenergic beta-1 Receptor Antagonists; Aged; Bisoprolol; China; Cohort Stu | 2018 |
Effects of anti-ischaemic drug therapy in silent myocardial ischaemia type I: the Swiss Interventional Study on Silent Ischaemia type I (SWISSI I): a randomized, controlled pilot study.
Topics: Acute Coronary Syndrome; Adrenergic beta-Antagonists; Adult; Aged; Amlodipine; Bisoprolol; Death, Su | 2007 |
4 other studies available for bisoprolol and Acute Coronary Syndrome
| Article | Year |
|---|---|
Genetic polymorphisms in ADRB1, ADRB2 and CYP2D6 genes and response to beta-blockers in patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Adrenergic beta-Antagonists; Bisoprolol; Cytochrome P-450 CYP2D6; Genotype; | 2023 |
An attempt at administering a transdermal formulation of bisoprolol in patients with acute cardiac symptoms.
Topics: Acute Coronary Syndrome; Acute Disease; Administration, Cutaneous; Adrenergic beta-1 Receptor Antago | 2021 |
[Patient age and CYP2D6*4/CYP2D6*3 genotype on maximal heart rate in patients after acute coronary syndrome treated with bisoprolol.]
Topics: Acute Coronary Syndrome; Aged; Bisoprolol; Cytochrome P-450 CYP2D6; Female; Genotype; Heart Rate; Hu | 2021 |
Population Pharmacokinetic Analysis of Bisoprolol in Patients With Acute Coronary Syndrome.
Topics: Acute Coronary Syndrome; Adrenergic beta-1 Receptor Antagonists; Adult; Aged; Aged, 80 and over; Bis | 2019 |